

**DRAFT
TOXICOLOGICAL PROFILE FOR
IODINE**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry**

September 2001

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

UPDATE STATEMENT

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology/Toxicology Information Branch
1600 Clifton Road NE, E-29
Atlanta, Georgia 30333

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public. We plan to revise these documents in response to public comments and as additional data become available. Therefore, we encourage comments that will make the toxicological profile series of the greatest use.

Comments should be sent to:

Agency for Toxic Substances and Disease Registry
Division of Toxicology
1600 Clifton Road, N.E.
Mail Stop E-29
Atlanta, Georgia 30333

Background Information

The toxicological profiles are developed by ATSDR pursuant to Section 104(i) (3) and (5) of the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund) for hazardous substances found at Department of Energy (DOE) waste sites. CERCLA directs ATSDR to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. ATSDR and DOE entered into a Memorandum of Understanding on November 4, 1992 which provided that ATSDR would prepare toxicological profiles for hazardous substances based upon ATSDR's or DOE's identification of need. The current ATSDR priority list of hazardous substances at DOE NPL sites was announced in the Federal Register on July 24, 1996 (61 FR 38451).

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

A handwritten signature in black ink, reading "Jeffrey P. Koplan". The signature is fluid and cursive, with the first name "Jeffrey" being more prominent than the last name "Koplan".

Jeffrey P. Koplan, M.D., M.P.H.
Administrator
Agency for Toxic Substances and
Disease Registry

QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by *type of health effect* (death, systemic, immunologic, reproductive), by *route of exposure*, and by *length of exposure* (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

Section 1.7	How Can (Chemical X) Affect Children?
Section 1.8	How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.7	Children's Susceptibility
Section 6.6	Exposures of Children

Other Sections of Interest:

Section 3.8	Biomarkers of Exposure and Effect
Section 3.11	Methods for Reducing Toxic Effects

ATSDR Information Center

Phone: 1-888-42-ATSDR or (404) 498-0110	Fax: (404) 498-0057
E-mail: atsdric@cdc.gov	Internet: http://www.atsdr.cdc.gov

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include *Reproductive and Developmental Hazards*; *Skin Lesions and Environmental Exposures*; *Cholinesterase-Inhibiting Pesticide Toxicity*; and numerous chemical-specific case studies.

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. *Contact:* NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. *Contact:* NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. *Contact:* NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. *Contact:* AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: <http://www.aoec.org/>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. *Contact:* ACOEM, 55 West Seegers Road, Arlington Heights, IL 60005 • Phone: 847-818-1800 • FAX: 847-818-9266.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHORS(S):

John Risher, Ph.D
ATSDR, Division of Toxicology, Atlanta, GA

Gary Diamond, Ph.D.
Richard Amata, Ph.D.
Stephen G. Swarts, Ph.D.
Syracuse Research Corporation, North Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Research Implementation Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.

PEER REVIEW

A peer review panel was assembled for iodine. The panel consisted of the following members:

1. Dr. Raymond Lloyd, Professor Emeritus of Radiobiology, University of Utah, 729 Arapahoe Dr., Salt Lake City, UT 84108-1218;
2. Dr. Kiyohiko Mabuchi, National Cancer Institute, 6120 Executive Boulevard, Rockville, MD 20852;
3. Dr. Marvin Rallison, Professor Emeritus of Pediatric Endocrinology and Metabolism, University of Utah School of Medicine, 1706 Oakridge Dr., Salt Lake City, UT 84106;
4. Dr. Noel R. Rose, Professor of Molecular Medicine, Johns Hopkins University, 615 North Wolfe St., Baltimore, MD 21205;
5. Dr. Roy E. Shore, Professor and Director, Division of Epidemiology and Biostatistics, New York University School of Medicine, 650 First Ave., New York, NY 10016-3240

These experts collectively have knowledge of iodine's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

CONTENTS

FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS	vii
CONTRIBUTORS	ix
PEER REVIEW	xi
LIST OF FIGURES	xvii
LIST OF TABLES	xix
1. PUBLIC HEALTH STATEMENT	1
1.1 WHAT IS IODINE?	1
1.2 WHAT HAPPENS TO IODINE WHEN IT ENTERS THE ENVIRONMENT?	2
1.3 HOW MIGHT I BE EXPOSED TO IODINE?	2
1.4 HOW CAN IODINE ENTER AND LEAVE MY BODY?	3
1.5 HOW CAN IODINE AFFECT MY HEALTH?	4
1.6 HOW CAN IODINE AFFECT CHILDREN?	4
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO IODINE?	5
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO IODINE?	6
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?	6
1.10 WHERE CAN I GET MORE INFORMATION?	7
2. RELEVANCE TO PUBLIC HEALTH	9
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO IODINE IN THE UNITED STATES	9
2.2 SUMMARY OF HEALTH EFFECTS	10
2.3 MINIMAL RISK LEVELS	23
3. HEALTH EFFECTS	27
3.1 INTRODUCTION	27
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	27
3.2.1 Inhalation Exposure	28
3.2.1.1 Death	29
3.2.1.2 Systemic Effects	30
3.2.1.3 Immunological and Lymphoreticular Effects	30
3.2.1.4 Neurological Effects	30
3.2.1.5 Reproductive Effects	31
3.2.1.6 Developmental Effects	31
3.2.1.7 Cancer	31
3.2.2 Oral Exposure	31
3.2.2.1 Death	36
3.2.2.2 Systemic Effects	37
3.2.2.3 Immunological and Lymphoreticular Effects	68
3.2.2.4 Neurological Effects	73
3.2.2.5 Reproductive Effects	74
3.2.2.6 Developmental Effects	76
3.2.2.7 Cancer	77

3.2.3	Dermal Exposure	97
3.2.3.1	Death	97
3.2.3.2	Systemic Effects	98
3.2.3.3	Immunological and Lymphoreticular Effects	100
3.2.3.4	Neurological Effects	101
3.2.3.5	Reproductive Effects	101
3.2.3.6	Developmental Effects	101
3.2.3.7	Cancer	102
3.2.4	External Exposure	102
3.2.4.1	Death	102
3.2.4.2	Systemic Effects	102
3.2.4.3	Immunological and Lymphoreticular Effects	102
3.2.4.4	Neurological Effects	102
3.2.4.5	Reproductive Effects	102
3.2.4.6	Developmental Effects	102
3.2.4.7	Cancer	102
3.2.5	Other Routes of Exposure	102
3.3	GENOTOXICITY	102
3.4	TOXICOKINETICS	104
3.4.1	Absorption	104
3.4.1.1	Inhalation Exposure	104
3.4.1.2	Oral Exposure	104
3.4.1.3	Dermal Exposure	107
3.4.1.4	Other Routes of Exposure	110
3.4.2	Distribution	110
3.4.2.1	Inhalation Exposure	110
3.4.2.2	Oral Exposure	110
3.4.2.3	Dermal Exposure	114
3.4.2.4	Other Routes of Exposure	114
3.4.3	Metabolism	114
3.4.3.1	Inhalation Exposure	114
3.4.3.2	Oral Exposure	115
3.4.3.3	Dermal Exposure	121
3.4.4	Elimination and Excretion	121
3.4.4.1	Inhalation Exposure	121
3.4.4.2	Oral Exposure	121
3.4.4.3	Dermal Exposure	123
3.4.4.4	Other Routes of Exposure	123
3.4.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	123
3.5	MECHANISMS OF ACTION	142
3.5.1	Pharmacokinetic Mechanisms	142
3.5.2	Mechanisms of Toxicity	148
3.5.3	Animal-to-Human Extrapolations	149
3.6	ENDOCRINE DISRUPTION	150
3.7	CHILDREN'S SUSCEPTIBILITY	151
3.8	BIOMARKERS OF EXPOSURE AND EFFECT	155
3.8.1	Biomarkers Used to Identify or Quantify Exposure to Iodine	156
3.8.2	Biomarkers Used to Characterize Effects Caused by Iodine	157
3.9	INTERACTIONS WITH OTHER CHEMICALS	159
3.10	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	162
3.11	METHODS FOR REDUCING TOXIC EFFECTS	164
3.11.1	Reducing Peak Absorption Following Exposure	164
3.11.2	Reducing Body Burden	164
3.11.3	Interfering with the Mechanism of Action for Toxic Effects	165

3.12	ADEQUACY OF THE DATABASE	165
3.12.1	Existing Information on Health Effects of Iodine	166
3.12.2	Identification of Data Needs	166
3.12.3	Ongoing Studies	171
4.	CHEMICAL, PHYSICAL, AND RADIOLOGICAL INFORMATION	173
4.1	CHEMICAL IDENTITY	173
4.2	PHYSICAL, CHEMICAL, AND RADIOLOGICAL PROPERTIES	173
5.	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	181
5.1	PRODUCTION	181
5.2	IMPORT/EXPORT	182
5.3	USE	182
5.4	DISPOSAL	182
6.	POTENTIAL FOR HUMAN EXPOSURE	185
6.1	OVERVIEW	185
6.2	RELEASES TO THE ENVIRONMENT	191
6.2.1	Air	192
6.2.2	Water	196
6.2.3	Soil	197
6.3	ENVIRONMENTAL FATE	199
6.3.1	Transport and Partitioning	199
6.3.2	Transformation and Degradation	203
6.3.2.1	Air	203
6.3.2.2	Water	205
6.3.2.3	Sediment and Soil	206
6.3.2.4	Other Media	206
6.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	206
6.4.1	Air	206
6.4.2	Water	207
6.4.3	Sediment and Soil	212
6.4.4	Other Environmental Media	212
6.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	216
6.6	EXPOSURES OF CHILDREN	222
6.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	224
6.8	ADEQUACY OF THE DATABASE	226
6.8.1	Identification of Data Needs	227
6.8.2	Ongoing Studies	229
7.	ANALYTICAL METHODS	231
7.1	BIOLOGICAL MATERIALS	231
7.1.1	Internal Iodine Measurements	231
7.1.2	External Measurements	237
7.2	ENVIRONMENTAL SAMPLES	240
7.2.1	Field Measurements of Iodine	240
7.2.2	Laboratory Analysis of Environmental Samples	240
7.3	ADEQUACY OF THE DATABASE	252
7.3.1	Identification of Data Needs	253
7.3.2	Ongoing Studies	253
8.	REGULATIONS AND ADVISORIES	255
9.	REFERENCES	273

10. GLOSSARY	415
--------------------	-----

APPENDICES

A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS	A-1
B. USER'S GUIDE	B-1
C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS	C-1
D. OVERVIEW OF BASIC RADIATION PHYSICS, CHEMISTRY AND BIOLOGY	D-1

LIST OF FIGURES

3-1. Levels of Significant Exposure to Iodine—Chemical Toxicity—Oral	45
3-2. Levels of Significant Exposure to Iodine—Radiation Toxicity—Oral	80
3-3. Pathways Uptake and Metabolism of Iodide in the Thyroid Gland	116
3-4. Thyroid Hormones and Metabolic Precursors	117
3-5. Pathways of Metabolism of Iodothyronines	119
3-6. Major Deiodination Pathways of Thyroid Hormones in Peripheral Tissues	120
3-7. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance	125
3-8. Respiratory Tract Compartments in Which Particles May be Deposited	127
3-9. Reaction of Gases or Vapors at Various Levels of the Gas-Blood Interface	129
3-10. Compartment Model to Represent Time-Dependent Particle Transport in the Respiratory Tract	133
3-11. The Human Respiratory Tract Model: Absorption into Blood	135
3-12. ICRP (1989) Metabolic Model for Iodine	137
3-13. NRPB-UK (1989) Metabolic Model for Iodine	139
3-14. Existing Information on Health Effects of Stable Iodine	167
3-15. Existing Information on Health Effects of Radioactive Iodine	168
6-1. Frequency of NPL Sites with Iodine Contamination	186
6-2. Frequency of NPL Sites with Iodine 129 Contamination	187
6-3. Frequency of NPL Sites with Iodine 131 Contamination	188
6-4. Geochemical Cycle of Triad Elements (I, Br, Cl)	193
6-5. An Outline of the Movement of Iodine in the Environment	194
6-6. Diagram of the Global Iodine Cycle at Steady State Showing Environmental Compartments, Compartment Inventories in Grams (g), Transport Pathways, and Fluxes in Grams per Year (g/year)	200
6-7. A Simplified Scheme of Iodine Cycling in the Marine Boundary Layer	204

LIST OF TABLES

2-1. Thyroid Doses and Dose Rates for Various Isotopes of Iodine ^a	13
2-2. Releases from Radioiodine-producing Events	17
3-1. Levels of Significant Exposure to Iodine—Chemical Toxicity—Oral	38
3-2. Levels of Significant Exposure to Iodine—Radiation Toxicity—Oral	78
3-3. Estimated Thyroid Radiation Doses in Populations Studied for Radioiodine-related Cancers	85
3-4. Binding Characteristics of Major Human Thyroid Hormone-Binding Proteins	112
3-5. Reference Respiratory Values for a General Caucasian Population at Different Levels of Activity	128
3-6. Reference Values of Parameters for the Compartment Model to Represent Time-dependent Particle Transport from the Human Respiratory Tract	131
3-7. Properties of Human Iodothyronine Selenodeiodinases	147
3-8. Typical Reference Ranges for Serum Thyroid Hormones and TSH in Humans	158
3-9. Ongoing Studies on Health Effects of Radioactive Iodine	172
4-1. Chemical Identity of Iodine and Iodine Compounds	174
4-2. Physical and Chemical Properties of Iodine and Iodine Compounds	176
4-3. Percent Natural Occurrence and Radioactive Properties of Isotopes of Iodine	179
6-1. Approximate Releases of ¹²⁹ I from Atmospheric and High Altitude Nuclear Weapons Tests . . .	208
6-2. Concentration of Iodine, Chloride, and ¹²⁹ I/ ¹²⁷ I Ratio in Air and Precipitation as a Function of Location and Collection Time	210
6-3. Iodine Content in Specific Soil Types	213
6-4. Iodine Content in Missouri Soils as a Function of Depth and Parent Material	214
6-5. Estimated Average Iodine Intake for Adults in the United States	218
7-1. Analytical Methods for Determining Iodine in Biological Samples	232
7-2. Analytical Methods for Determining Radioiodine in Biological Samples	238
7-3. Analytical Methods for Determining Iodine in Environmental Samples	241
7-4. Analytical Methods for Determining Radioiodine in Environmental Samples	246
8-1. Regulations and Guidelines Applicable to Stable Iodine	256
8-2. Regulations and Guidelines Applicable to Radioactive Iodine	260
8-3. Dose Coefficients ^a (e(50)) for Intakes of Iodine Radionuclides	272